SkinDerm Cosmeceutics has laid the foundations of its expansion plans which will consist of a B2B private label service.
SkinDerm Cosmeceutics has unveiled its plans to enter the B2B private label manufacturing service as well as the Pharmaceutical market. Under its proposed plans SkinDerm Cosmeceutics will be seeking to purchase a new manufacturing site in the UK where it will seek to become MHRA accredited.
It is to introduce a B2B aspect to its business where it will be providing a private label manufacturing service of skincare products ranging from spa grade and salon grade products, to the pharmaceutical grade OTC sector for MHRA approved pharmaceutical preparations. facials mask
Currently, it is providing vitamins and supplements which are manufactured in the UK to GMP standards and ISO:9001 certifications. The vitamins will not be part of the private label business.
A statement from SkinDerm Cosmeceutics said:
“The MHRA accredited facility would allow us to enter the OTC Pharmaceutical market where we would be able to work tirelessly to research and manufacture revolutionary skin care treatments that make a difference to people’s lives. In addition to this, our spa-grade and cosmetic grade products will be available for businesses on a private label/ white label scheme. We will be offering a complete internal end to end service from concept, manufacturing, testing, packaging, filling and labeling to a finished product. We will be able to create products on a large scale for retailers, pharmacies, salons, spas, and hotels on an international level. On the other hand, we understand how difficult it is for new start-up companies and niche brands due to the pressure of high volume order requirements; therefore we would also be offering very low minimum quantities. In fact, we will be one of the lowest in the industry. Together we can help small businesses create their own dream brand. The low minimum order quantity would be an excellent place for someone to start their journey to their own successful quality brand.”
Further information will be released once the site facility has been approved and finalised and all automated pharmaceutical equipment has been fully fitted and tested.
For further information and to stay updated please visit www.skinderm.co.uk